The Journal of Immunology, Vol 157, Issue 2 656-660, Copyright © 1996 by American Association of Immunologists

ARTICLES

p70 S6 kinase sensitivity to rapamycin is eliminated by amino acid substitution of Thr229

H Sugiyama, P Papst, EW Gelfand and N Terada
Division of Basic Sciences, Department of Pediatrics, National Jewish Center for Immunology and Respiratory Medicine, Denver, CO 80206, USA.

Rapamycin, which forms a complex with FK506-binding protein and FK506- binding protein-rapamycin-associated protein, induces immunosuppression through an as yet undefined pathway. Our previous studies demonstrated that rapamycin inactivates p7Os6k, which results in the inhibition of translation of ribosomal proteins. Here, we analyzed the mechanism of inactivation of p70s6k by rapamycin using site-directed mutagenesis of the phosphate acceptor site. We introduced a point mutation at Thr229 in the catalytic subdomain VIII of p7Os6k because Thr229 of p7Os6k corresponds to the phosphorylation site of mitogen-activated protein kinases by mitogen-activated protein kinase kinase and to the autophosphorylation site of protein kinase A whose phosphorylation is required for its full activation. Thr229 of rat p70s6k was substituted by either a neutral amino acid Ala (T229A) or by an acidic amino acid Glu (T229E). T229A-P70s6k, expressed in COS cells, migrated faster in SDS-polyacrylamide gels than wild-type p70s6k, and this mutation completely ablated the catalytic activity of the kinase. In contrast, T229E-p70s6k migrated more slowly in SDS-polyacrylamide gels, but demonstrated partial kinase activity (approximately 20% compared with the wild type). These data indicate that the negative charge at Thr229 which is normally achieved by phosphorylation of the residue, is important for the catalytic function of p70s6k. Further, the residual activity of T229E-p70s6k was not affected by rapamycin, implying that rapamycin-induced inactivation of p70s6k may be caused by dephosphorylation or impaired phosphorylation of Thr229.

This article has been cited by other articles:

				A. Vazquez-Martin, C. Oliveras-Ferraros, R. Colomer, J. Brunet, and J. A. Menendez Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb(R)) in human breast carcinoma cells Ann. Onc., June 1, 2008; 19(6): 1097 - 1109. [Abstract] [Full Text] [PDF]

				O. J. Shah and T. Hunter Critical Role of T-Loop and H-Motif Phosphorylation in the Regulation of S6 Kinase 1 by the Tuberous Sclerosis Complex J. Biol. Chem., May 14, 2004; 279(20): 20816 - 20823. [Abstract] [Full Text] [PDF]

				M. B. Dilling, G. S. Germain, L. Dudkin, A. L. Jayaraman, X. Zhang, F. C. Harwood, and P. J. Houghton 4E-binding Proteins, the Suppressors of Eukaryotic Initiation Factor 4E, Are Down-regulated in Cells with Acquired or Intrinsic Resistance to Rapamycin J. Biol. Chem., April 12, 2002; 277(16): 13907 - 13917. [Abstract] [Full Text] [PDF]

				J. F. GUMMERT, T. IKONEN, and R. E. MORRIS Newer Immunosuppressive Drugs: A Review J. Am. Soc. Nephrol., June 1, 1999; 10(6): 1366 - 1380. [Abstract] [Full Text]

				P. J. Papst, H. Sugiyama, M. Nagasawa, J. J. Lucas, J. L. Maller, and N. Terada Cdc2-Cyclin B Phosphorylates p70 S6 Kinase on Ser411 at Mitosis J. Biol. Chem., June 12, 1998; 273(24): 15077 - 15084. [Abstract] [Full Text] [PDF]